NAM
TGTX icon

Nexpoint Asset Management’s TG Therapeutics TGTX Stock Holding History

Nexpoint Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-110,760
Closed -$1.23M – 273
2019
Q4 		$1.23M Sell
110,760
-538,700
-83% -$4.1M 0.09% 129
2019
Q3 		$3.65M Buy
+649,460
New +$4.53M 0.23% 63

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nexpoint Asset Management's TGTX Position: Q1 2020 in Review

Nexpoint Asset Management sold out of TG Therapeutics (TGTX) in Q1 2020, closing a stake of 110,760 shares — an estimated $1.23M sold.

Nexpoint Asset Management first reported a position in TGTX in Q3 2019 and held it in 2 quarters. The position peaked at $3.65M in Q3 2019. 146 funds tracked by Wall St. Rank hold TGTX as of Q1 2020.

  • Nexpoint Asset Management reported no remaining TG Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Nexpoint Asset Management sold 110,760 TG Therapeutics shares in Q1 2020, an estimated $1.23M.
  • Nexpoint Asset Management first reported a position in TG Therapeutics in Q3 2019 and held it in 2 quarters.
  • Nexpoint Asset Management's TG Therapeutics position peaked at $3.65M in Q3 2019.
  • 146 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2020.

Based on Nexpoint Asset Management's 13F filing for Q1 2020, filed 15 May 2020.